# ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

> **NCT02362048** · PHASE2 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 77 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** ACP-196
- **DRUG:** ACP-196 in combination with pembrolizumab

## Key facts

- **NCT ID:** NCT02362048
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2019-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02362048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02362048, "ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02362048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*